中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导职责，并 出具 2025 年半年度（以下简称"本持续督导期间"）跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 29 日、2025 年 9 月 3 日对公司进行了现场检 查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审 ...

Group 1 - The core viewpoint of the news is that Yahuang Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in revenue and a high level of financing balance [1][2] - On September 15, Yahuang Pharmaceutical's stock price decreased by 0.86%, with a trading volume of 1.05 billion yuan, and a net financing purchase of 640.96 million yuan [1] - As of September 15, the total financing and securities balance for Yahuang Pharmaceutical was 2.35 billion yuan, which represents 4.69% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of June 30, the number of shareholders for Yahuang Pharmaceutical increased to 25,500, reflecting a growth of 2.09%, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2] - For the first half of 2025, Yahuang Pharmaceutical reported a revenue of 1.30 billion yuan, marking a year-on-year growth of 61.80%, although the net profit attributable to the parent company was -1.62 billion yuan, an increase of 11.84% compared to the previous period [2] - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, which is an increase of 891,300 shares from the previous period [2]

江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 1 | 《关于修订、制定公司部分治理制度的议案》 9 | | --- | 江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会须知 为了保证股东在本次股东大会依法行使职权，确保股东大会的正常秩序和 议事效率，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）、《江苏亚虹医药科技股份有限公司股东大会议事规则》等有关规 定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）特制 定本次股东大会会议须知： 一、为确认出席大会的股东及股东代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席大会的股东或股东代理人或其他出席者提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有的表 决权数量之前，会议登记应当终止。会议登记终止后进场的股东无权参与现 ...

Core Viewpoint - Yahui Pharmaceutical (688176.SH) is currently experiencing a decline in stock price, closing at 11.51 yuan with a drop of 4.88%, indicating a state of share price below the initial public offering (IPO) price [1] Summary by Relevant Sections Company Overview - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at an IPO price of 22.98 yuan per share [1] - The company is controlled by PAN KE, who serves as the chairman and general manager, holding American nationality [1] IPO Details - The total funds raised from the IPO amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net funds raised exceeded the original plan by 311 million yuan, which was initially set at 2.070 billion yuan [1] - The total issuance costs were 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Stock Performance - The stock price fell below the IPO price on the first day of trading, with an intraday high of 20.00 yuan, marking the highest price since the listing [1]

Group 1 - The core viewpoint of the news is that Yahui Pharmaceutical experienced a decline in stock price, with a drop of 5.04% to 11.49 CNY per share, and a trading volume of 209 million CNY, resulting in a total market capitalization of 6.563 billion CNY [1] - Yahui Pharmaceutical, established on March 16, 2010, and listed on January 7, 2022, focuses on the research, production, and sales of innovative drugs, with 96.34% of its revenue coming from anti-tumor products [1] Group 2 - Among the top ten circulating shareholders of Yahui Pharmaceutical, Penghua Fund holds a significant position, with its Penghua Medical Technology Stock A (001230) increasing its holdings by 891,300 shares in the second quarter, totaling 6.5441 million shares, which represents 1.73% of the circulating shares [2] - The latest scale of Penghua Medical Technology Stock A is 1.987 billion CNY, with a year-to-date return of 95.32%, ranking 18 out of 4222 in its category, and a one-year return of 111.48%, ranking 146 out of 3798 [2]

Group 1 - The core point of the news is the significant trading activity of Yahu Medicine-U, with a notable block trade occurring on September 5, involving 737,000 shares and a transaction value of 9.0135 million yuan at a price of 12.23 yuan per share [1][2] - The buyer of the block trade was CITIC Securities Co., Ltd. Suzhou Binhe Road Securities Business Department, while the seller was CITIC Securities Co., Ltd. Suzhou Branch [1] - Over the past three months, Yahu Medicine-U has recorded a total of two block trades, with a cumulative transaction value of 11.0204 million yuan [1] Group 2 - As of September 5, Yahu Medicine-U's closing price was 12.23 yuan, reflecting an increase of 2.60%, with a daily turnover rate of 4.24% and a total trading volume of 222.3 million yuan [1] - The stock has seen a net inflow of 927,000 yuan in main funds for the day, while over the past five days, the stock has increased by 5.61%, but there has been a cumulative net outflow of 25.3623 million yuan [1] - The latest margin financing balance for the stock is 240 million yuan, with a decrease of 2.6782 million yuan over the past five days, representing a decline of 1.10% [2] Group 3 - In terms of institutional ratings, one institution has provided a rating for the stock in the past five days, with the highest target price estimated by Pacific Securities at 15.68 yuan as of September 1 [2]

Group 1 - The company, Yahui Pharmaceutical, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry organized by the Shanghai Stock Exchange [2] - The event is scheduled for September 16, 2025, from 15:00 to 17:00 [2]

Group 1 - On September 5, Yahui Pharmaceutical executed a block trade of 737,000 shares, with a transaction amount of 9.0135 million yuan, accounting for 3.88% of the total trading volume for the day [1] - The transaction price was 12.23 yuan, which was flat compared to the market closing price of 12.23 yuan [1][2] - The trade was facilitated by CITIC Securities Co., Ltd., with the transaction occurring through its Suzhou branch [2]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-036 重要内容提示： （网址：http://roadshow.sseinfo.com/） 江苏亚虹医药科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司将参加由上海证券交易所主办的 2025 年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动的方式召开，公司将针对 2025 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 1 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会议召开地点：上海证券交易所上证路演中心 江苏亚虹医药科技股份有限公司 关于参加 2025年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会议召开方式：上证路演中心视频结合网络互动 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-035 江苏亚虹医药科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 23 日10 点 00 分 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 召开地点：上海市浦东新区高科西路 551 号万信酒店一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 23 日 1 股东大会召开日 ...